EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

MTAP protein status is highly concordant with CDKN2A fluorescent in situ hybridization and allows stratification of the luminal subtype in muscle‐invasive bladder cancer

Ekaterina Olkhov-Mitsel iD, Alexander Oberc iD, Kenneth J Craddock iD, Christopher Sherman, Elzbieta Slodkowska, Michelle R Downes iD

Histopathology · 2025

DOI: 10.1111/his.15324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von Ekaterina Olkhov-Mitsel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Anatomic Pathology, Department of Laboratory Medicine and Molecular Diagnostics, Precision Diagnostics and Therapeutics Program, Sunnybro…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cyclin-Dependent Kinase Inhibitor p16, In Situ Hybridization, Fluorescence, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Laboratory Medicine and Molecular Diagnostics Strategic Innovation Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Loss of heterozygosity in chromosome 9p21, common in urothelial carcinoma (UC), typically involves deletion of CDKN2A and MTAP genes. MTAP loss is emerging as a promising therapeutic target and predictive biomarker in UC. This single‐centrre retrospective study examined the incidence of CDKN2A deletions and MTAP loss in muscle‐invasive bladder cancer (MIBC) and metastatic urothelial carcinoma (mUC), investigating their correlations with clinical, pathological, and genomic features, as well as patient outcomes.

Methods

Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were performed on 302 MIBC specimens and 63 biopsy‐proven metachronous urothelial metastases to assess CDKN2A deletions and MTAP protein expression.

Results

CDKN2A homozygous deletion (HD), identified in 30.3% of MIBCs, and MTAP loss, found in 28.8% of MIBCs, were both significantly associated with the luminal‐URO subtype, FGFR3 mutations, and normal/wildtype p53 IHC ( P < 0.05). Loss of MTAP expression was significantly correlated with CDKN2A HD, with 84.0% sensitivity, 92.3% negative predictive value (NPV), 96.3% specificity, and 91.9% positive predictive value (PPV). MTAP expression was 100% concordant between primary tumours and nodal metastases. Patients with MTAP loss had a higher incidence of visceral metastases (50%) compared to bone/soft tissue (35.7%) and nodes (14.3%). Mean progression‐free survival and overall survival were shorter for patients with MTAP loss, although not statistically significant.

Conclusion

Our findings highlight CDKN2A HD and MTAP loss as prevalent genetic alterations in MIBC and mUC, particularly within the luminal‐URO subtype and FGFR3 ‐mutated, p53‐normal/wildtype tumours. MTAP IHC can serve as a surrogate marker for 9p21.3 HD, highlighting its clinical relevance and potential as a therapeutic target and predictive biomarker in MIBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCyclin-Dependent Kinase Inhibitor p16In Situ Hybridization, FluorescenceBiomarkers, TumorHumansMaleFemaleAgedMiddle AgedRetrospective StudiesCarcinoma, Transitional CellAged, 80 and overImmunohistochemistryAdultLoss of HeterozygosityPurine-Nucleoside Phosphorylase

Stichwörter der Autor:innen

9p21 lossCDKN2A deletionsMTAP lossmetastatic urothelial carcinomamolecular subtypingmuscle‐invasive bladder cancerp16prognostic biomarkerstherapeutic targets

Substanzen

Cyclin-Dependent Kinase Inhibitor p16Biomarkers, TumorCDKN2A protein, human5'-methylthioadenosine phosphorylasePurine-Nucleoside Phosphorylase

Autor:innen und Institutionen

  • Division of Anatomic Pathology, Department of Laboratory Medicine and Molecular Diagnostics, Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: Ekaterina Olkhov-Mitsel, Alexander Oberc, Kenneth J Craddock, Michelle R Downes

Förderung

  • Laboratory Medicine and Molecular Diagnostics Strategic Innovation Fund

Zitieren

APA

Olkhov-Mitsel, E., Oberc, A., Craddock, K. J., Sherman, C., Slodkowska, E., & Downes, M. R. (2025). MTAP protein status is highly concordant with CDKN2A fluorescent in situ hybridization and allows stratification of the luminal subtype in muscle‐invasive bladder cancer. Histopathology. https://doi.org/10.1111/his.15324

Vancouver

Olkhov-Mitsel E, Oberc A, Craddock KJ, Sherman C, Slodkowska E, Downes MR. MTAP protein status is highly concordant with CDKN2A fluorescent in situ hybridization and allows stratification of the luminal subtype in muscle‐invasive bladder cancer. Histopathology. 2025. doi:10.1111/his.15324

BibTeX
@article{OlkhovMitsel2025,
  author = {Olkhov-Mitsel, Ekaterina and Oberc, Alexander and Craddock, Kenneth J and Sherman, Christopher and Slodkowska, Elzbieta and Downes, Michelle R},
  title = {MTAP protein status is highly concordant with CDKN2A fluorescent in situ hybridization and allows stratification of the luminal subtype in muscle‐invasive bladder cancer},
  journal = {Histopathology},
  year = {2025},
  doi = {10.1111/his.15324}
}
Kostenlos starten →